Frontline Pembrolizumab Plus Chemo Shows Promise in Ovarian Cancer

1st-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab, followed by pembrolizumab maintenance, appeared feasible and safe for patients with advanced ovarian cancer, preliminary data from a small clinical trial suggested.

Source

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply